Carina is pleased to present preclinical data evaluating its LGR5-Targeted CAR-T cell therapy in human cancer models at the 8th CAR-TCR Summit held in Boston. More information in our release: bit.ly/45fGs0b #CART #CellTherapy

Carina is on the cusp of enrolling the first patient into a Phase 1 clinical trial studying its single dose CAR-T therapy in colorectal cancer. Find out more about this groundbreaking new treatment option in The Australian Business Review article: bit.ly/3KYEBoh

Super proud to see our CAR-T cells in solid tumours publication out in Nature Communications this week rdcu.be/dlPJwA A huge collaborative effort by many within Carina Biotech and enabled by staff and students Centre for Cancer Biology Uni of Adelaide Seattle Children's

Carina is pleased to be part of the 7th Annual Cell & Gene Therapy World Asia 2023 Conference to present Carina’s success getting its CAR-T asset to clinical trials. CEO Dr Rathjen will also speak on a leadership panel to share her extensive experience: bit.ly/3sUKT23

Carina will be holding its annual general meeting Tuesday 14 November, with a review of 2023 progress and anticipated clinical milestones in 2024. More to come!

First patient enrolled! A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer | ClinicalTrials.gov : bit.ly/47rI5Zb

Carina is pleased to announce it has dosed the first patient in its Phase 1/2a LGR5-targeting CAR-T therapy (CNA3103) for advanced colorectal cancer, a significant milestone as Carina advances its potentially revolutionary targeted cancer treatment option: bit.ly/41wiIE0

Join us in Melbourne tomorrow as CEO & Managing Director Dr Deborah Rathjen presents Carina’s first-in-class CAR-T treatment CNA3103 for colon cancer at Monsoon Communications' Twilight investor briefing!

Carina is pleased be presenting 3 posters from studies of its LGR5-targeting CAR-T program in colorectal and ovarian cancer at the AACR Annual Meeting in San Diego, 5-10 Apr. More detail on the poster presentations can be found in our press release: bit.ly/3PsG7RS

CEO & MD Dr Deborah Rathjen, Dr Carmela Ricciardelli, Dr Veronika Bandara & Annabell Leske presented posters on Carina’s LGR5-targeting CAR-T program at #AACR24. The posters were well attended & drew interest from pharma & investors. View the posters: bit.ly/3UnNQ6k

Join us at our #BiotechShowcase on Wed 21 Aug for a series of top Aussie #biotech presentations, panel on biotech investing and networking drinks. Don’t miss out: peak.contact

Hear how Carina Biotech’s lean team of 5 is advancing personalised CAR-T therapies targeting colorectal, ovarian & gastric cancers. 🌟 Phase 2 expected H2 2025. Tune in now Marcus Today ⬇️ bit.ly/3Znnfrs

Our CEO, Dr Deborah Rathjen, joins the AU CAR-T Showcase on Tue, 12 Aug in Melbourne, hosted by Monsoon Communications & FB Rice. 🔗 Register: bit.ly/reg-cart #CART #Biotech #ASX #CancerResearch

Our CEO, Dr Deborah Rathjen, will moderate the investor panel at #BiotechShowcase 2025 hosted by @PeakAsset & Monsoon Communications—joined by experts from Bioshares, UniseedFund & Tenmile. 🔗Register now: bit.ly/ZOOM-BiotechSh…